Beijing Bio has the same effect as Kexing Bio, among which Beijing Bio-vaccine is the first domestic inactivated vaccine approved by COVID-19, and the antibody can be produced after the first injection 10 day. After two injections, high titer antibody can be produced after 14 days, forming effective protection; Beijing Kexing vaccine has a very obvious protective effect and has been proved to have a protective effect on mutant strains in all countries.
At present, several COVID-19 vaccines approved by China are inactivated vaccines, and there is no evidence to show which company produces the best vaccine. So don't deliberately choose, as long as the vaccine has been officially approved by the state, you can rest assured that you can vaccinate. At present, COVID-19 vaccine brands approved by China are:
Brand 1: Inactivated COVID-19 Vaccine of Sinopharm North Medical Biology
(1) Company Profile
Beijing Institute of Biological Products was established in 19 19. Its predecessor was the Central Epidemic Prevention Department of Beiyang Government, which was the first specialized agency for national health and epidemic prevention and serum vaccine research and production in the history of China. 20 1 1 10 In June, Beijing Institute of Biological Products completed the restructuring and officially changed its name to Beijing Institute of Biological Products Co., Ltd.
(2) Protection efficiency
China Bio-COVID-19 Vaccine of Sinopharm Group passed the WHO emergency use certification and became the sixth vaccine on the WHO emergency use list, with an effective rate of over 70% and good safety.
Brand 2: Beijing Kexing Zhongxin Crown Vaccine
(1) Company Profile
Beijing Kexing Zhongwei Biotechnology Co., Ltd. was established on May 7, 2009, and its business scope includes research and development of biological vaccine technology; Diagnostic kit technology, providing technical services, etc. On February 6th, 20021,the State Administration of Pharmaceutical Products approved the novel coronavirus inactivated vaccine Kelaifu developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. (hereinafter referred to as "Kexing Zhongwei") to be listed in China conditionally.
(2) Protection efficiency
On May 13, the good news of China Kexing vaccine came from Indonesia. For 25,000 local medical staff with high-risk infection, the effective rate of infection prevention was 94%, and the prevention rate of infection death was 100%.
Brand 3: Wuhan Bio-COVID-19 Vaccine
(1) Company Profile
Wuhan Institute of Biological Products Co., Ltd. was incorporated in Jiangxia District Market Supervision Administration of Wuhan on March 8, 1990. On February 28th, 2002 1, the inactivated novel coronavirus vaccine jointly developed by Wuhan Biological Products Co., Ltd. and Institute of Virology, China Academy of Sciences was officially launched, with an annual output of1100 million doses.
(2) Protection efficiency
The safety of COVID-19 inactivated vaccine inoculated by China Institute of Biological Products of Sinopharm Group is good. After two doses of immunization, the vaccinators all produced high titer antibodies, and the positive conversion rate of neutralizing antibodies was 99.06%. The protective effect of the vaccine against diseases caused by COVID-19 virus infection (coronavirus pneumonia-19) was 72.5 1%.
Brand four: Anhui Zhifeilong horse new crown vaccine
(1) Company Profile
Anhui Zhifeilong Kyle Biopharmaceutical Co., Ltd. is a high-tech enterprise integrating research, development, production and sales of biological products, and a wholly-owned subsidiary of Chongqing zhifei Biological Products Co., Ltd. (stock code: 300 122).
(2) Protection efficiency
The data show that 76% of people can produce neutralizing antibodies after ZF200 1 is inoculated with two doses of vaccine. After three doses of vaccine, 97% people can produce neutralizing antibodies. The geometric mean titer (GMT) of the antibody reached 102.5, which exceeded the neutralizing antibody level of 89 serum samples of recovered patients in COVID-19.
Brand 5: Kangxinuo COVID-19 Vaccine
(1) Company Profile
Kangxinuo Bio-Co., Ltd. was established in Tianjin, China on June 5438+1October 65438+March, 2009, and is committed to the research, development, production and commercialization of innovative vaccines for public health in China and the world.
(2) Protection efficiency
The mid-term analysis of the third phase clinical trial showed that the overall protective effect of the vaccine on all symptoms was 65.28% after 28 days of single needle inoculation. After single-dose inoculation/0/4 days, the overall protective effect of vaccine on all symptoms was 68.83%. After 28 days of single-needle vaccination, the protective effect of vaccine on severe diseases was 90.07%. 95.47% after single needle inoculation 14 days.